Neurology
Found 11 results
Filters: Keyword is Multiple Sclerosis, Relapsing-Remitting  [Clear All Filters]
2019
Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.  2019.  Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.. BMC Neurol. 19(1):116.
Zhang S, Nguyen TD, Rúa SMHurtado, Kaunzner UW, Pandya S, Kovanlikaya I, Spincemaille P, Wang Y, Gauthier SA.  2019.  Quantitative Susceptibility Mapping of Time-Dependent Susceptibility Changes in Multiple Sclerosis Lesions.. AJNR Am J Neuroradiol. 40(6):987-993.
2018
Azary S, Schreiner T, Graves J, Waldman A, Belman A, Guttman BWeinstock, Aaen G, Tillema J-M, Mar S, Hart J et al..  2018.  Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis.. J Neurol Neurosurg Psychiatry. 89(1):28-33.
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
Chiang GC, Hu J, Morris E, Wang Y, Gauthier SA.  2018.  Quantitative Susceptibility Mapping of the Thalamus: Relationships with Thalamic Volume, Total Gray Matter Volume, and T2 Lesion Burden.. AJNR Am J Neuroradiol. 39(3):467-472.
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.. Mult Scler. 24(4):553-554.
2017
Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G.  2017.  No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.. Mult Scler. 23(13):1736-1747.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K et al..  2017.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.. N Engl J Med. 376(3):221-234.
2016
Chiang GC, Pinto S, Comunale JP, Gauthier SA.  2016.  Gadolinium-Enhancing Lesions Lead to Decreases in White Matter Tract Fractional Anisotropy in Multiple Sclerosis.. J Neuroimaging. 26(3):289-95.
2013
Reardon J, Perumal JS.  2013.  Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.. Drug Des Devel Ther. 7:1187-93.
2012
Perumal JS, Foo F, Cook P, Khan O.  2012.  Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.. Mult Scler. 18(8):1197-9.